CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Phase 1/2 Recruiting
152 enrolled
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Phase 1/2 Recruiting
70 enrolled
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Phase 1/2 Recruiting
200 enrolled
OPAL
Phase 1/2 Recruiting
144 enrolled
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Phase 1/2 Recruiting
270 enrolled
MK-3475-G21
Phase 1/2 Recruiting
20 enrolled
QUADvance
Phase 1/2 Recruiting
178 enrolled
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Phase 1/2 Recruiting
155 enrolled
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Phase 1/2 Recruiting
32 enrolled
MK-3475-051
Phase 1/2 Recruiting
370 enrolled
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Phase 1/2 Recruiting
160 enrolled
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
Phase 1/2 Recruiting
60 enrolled
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Phase 1/2 Recruiting
126 enrolled
CAVALRY
Phase 1/2 Recruiting
104 enrolled
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Phase 1/2 Recruiting
180 enrolled
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Phase 1/2 Recruiting
63 enrolled
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Phase 1/2 Recruiting
12 enrolled
SELECT-CAR-NK
Phase 1/2 Recruiting
85 enrolled
PlaTform
Phase 1/2 Recruiting
49 enrolled
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
Phase 1/2 Recruiting
41 enrolled
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Phase 1/2 Recruiting
90 enrolled
Avo In R/R And Previously Untreated MCL
Phase 1/2 Recruiting
72 enrolled
A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies
Phase 1/2 Recruiting
50 enrolled
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
Phase 1/2 Recruiting
135 enrolled
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Phase 1/2 Recruiting
60 enrolled
GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma
Phase 1/2 Recruiting
40 enrolled
ANXIN-02
Phase 1/2 Recruiting
24 enrolled
Mosunetuzumab for CLL MRD Clearance
Phase 1/2 Recruiting
40 enrolled
SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Phase 1/2 Recruiting
12 enrolled
DAHLIA
Phase 1/2 Recruiting
85 enrolled
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Phase 1/2 Recruiting
75 enrolled
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Phase 1/2 Recruiting
120 enrolled
Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma
Phase 1/2 Recruiting
99 enrolled
STARLIGHT-1
Phase 1/2 Recruiting
21 enrolled
BAH2573-103
Phase 1/2 Recruiting
60 enrolled
PRIMAVERA
Phase 1/2 Recruiting
110 enrolled
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Phase 1/2 Recruiting
275 enrolled
A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
Phase 1/2 Recruiting
224 enrolled
CAR-NK
Phase 1/2 Recruiting
6 enrolled
CAR-T
Phase 1/2 Recruiting
90 enrolled
Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma
Phase 1/2 Recruiting
15 enrolled
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Phase 1/2 Recruiting
20 enrolled
CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
Phase 1/2 Recruiting
80 enrolled
CARTHEDRALL
Phase 1/2 Recruiting
81 enrolled
MZL-001
Phase 1/2 Recruiting
35 enrolled
TSN222 in Subjects With Advanced Solid Tumors or Lymphomas
Phase 1/2 Recruiting
162 enrolled
CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors
Phase 1/2 Recruiting
80 enrolled
CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma
Phase 1/2 Recruiting
30 enrolled